Most of us learned a tidy story in biology class: XX chromosomes make a female, XY chromosomes make a male, and that is the whole picture. It is a useful simplification — and it is wrong. A person with XY chromosomes can be born with a vulva, develop breasts at puberty, and carry a pregnancy to term. A person with XX chromosomes can be born with a penis and testes. A person can have XXY chromosomes, or a mixture of XX and XY cells in different parts of their body. These are not exotic anomalies confined to medical textbooks. They are naturally occurring variations in human sex development that, by some estimates, affect as many as 1 in 60 people.
The umbrella term for these variations is intersex — sometimes called differences of sex development (DSD) in clinical settings. Intersex is not a single condition but a broad category encompassing dozens of distinct biological variations in chromosomes, hormones, gonads, or anatomy that do not fit neatly into the binary categories of male or female.
Despite their prevalence, intersex variations remain poorly understood by the general public and, in many cases, by healthcare providers themselves. This knowledge gap has real consequences: unnecessary surgeries on infants, delayed diagnoses, inadequate hormone management, and psychological harm from secrecy and stigma. This article walks through the biology, the most common variations, the healthcare considerations, and the ongoing debate over how medicine should — and should not — intervene.
Sex Development Is a Process, Not a Switch
To understand intersex variations, you first need to understand how sex development actually works — because it is far more complex than a single gene flipping a single switch.
Sex development unfolds in stages over several weeks of fetal development, and each stage involves a cascade of genetic signals, hormone production, and tissue responses that must all align in a specific sequence. When any step in this cascade diverges from the typical pathway, the result is an intersex variation.
Stage 1: Chromosomal sex. At fertilization, the embryo typically receives either two X chromosomes (46,XX) or one X and one Y (46,XY). But variations occur here too — some individuals are 45,X (a single X), others are 47,XXY, and some have mosaic karyotypes where different cells carry different chromosome combinations.
Stage 2: Gonadal development. Around week 6-7 of gestation, the bipotential gonad begins to differentiate. In most 46,XY embryos, the SRY gene on the Y chromosome triggers development of testes. In most 46,XX embryos, the absence of SRY leads to ovarian development. But SRY is not the only player — genes like SOX9, WNT4, RSPO1, and DAX1 all participate, and variations in any of them can alter the outcome. A 46,XX person can develop testes if SOX9 is duplicated. A 46,XY person can develop ovaries if SRY is deleted or non-functional.
Stage 3: Hormonal environment. Once gonads form, they produce hormones — primarily testosterone and anti-Mullerian hormone (AMH) from testes, or estrogen from ovaries. These hormones drive the development of internal reproductive structures and external genitalia. But the body must also be able to respond to these hormones, which requires functional receptors. If the androgen receptor does not work properly, a body bathed in testosterone will not masculinize — regardless of how much testosterone is present.
Stage 4: Anatomical development. External genitalia develop from the same precursor structures in all embryos. The genital tubercle becomes either a clitoris or a penis; the labioscrotal folds become either labia or a scrotum. The degree of masculinization depends on the timing, amount, and receptor sensitivity to androgens. This is a continuum, not a binary — which is why genital anatomy exists on a spectrum.
A 2015 review in Nature by Claire Ainsworth summarized it well: sex is not a single trait determined by a single gene. It is a network of interacting features — chromosomes, gene expression, hormone levels, receptor sensitivity, and anatomy — each of which can vary independently. The result is far more biological diversity than the male/female binary suggests.
How Common Are Intersex Variations?
Prevalence estimates for intersex variations depend heavily on how the category is defined — and this is itself a matter of debate.
The most frequently cited figure comes from a 2000 analysis by Anne Fausto-Sterling, published in the American Journal of Human Biology, which estimated that approximately 1.7% of live births involve some form of intersex variation. This figure includes a broad range of conditions, from chromosomal variations like Klinefelter syndrome (47,XXY) and Turner syndrome (45,X) to hormonal conditions like congenital adrenal hyperplasia (CAH) and androgen insensitivity syndrome (AIS), to anatomical variations in genital or gonadal development.
Some clinicians argue this estimate is too broad. A 2002 response by Leonard Sax in the Journal of Sex Research proposed a narrower definition that excluded conditions where chromosomal sex is consistent with phenotypic sex (like Klinefelter and Turner syndromes), arriving at a prevalence of approximately 0.018% — roughly 1 in 5,500 births. However, this narrower definition has been criticized for being arbitrarily restrictive and for excluding conditions that genuinely affect sex development and require medical monitoring.
The Endocrine Society and multiple peer-reviewed analyses support a middle range. A 2018 review in European Journal of Endocrinology by Arlt and colleagues estimated that conditions affecting sex development collectively occur in roughly 1 in 200 to 1 in 300 live births when chromosomal variations are included, and approximately 1 in 4,500 to 1 in 5,500 when restricted to atypical genitalia noticeable at birth.
What all estimates agree on: intersex is not rare. Even the most conservative figures yield tens of thousands of affected births per year in the United States alone. The broader estimates suggest a population comparable in size to people with red hair.
Common Intersex Variations: A Closer Look
Intersex is not a single condition — it encompasses dozens of distinct biological variations. Here are some of the most common.
Congenital Adrenal Hyperplasia (CAH)
Prevalence: Approximately 1 in 15,000 births for the classic form; late-onset (non-classic) CAH affects roughly 1 in 200 people of certain ethnic backgrounds.
What it is: CAH is a group of autosomal recessive genetic disorders affecting the adrenal glands. The most common form involves a deficiency of the enzyme 21-hydroxylase, which the adrenal glands need to produce cortisol. Without adequate 21-hydroxylase, the adrenal glands overproduce androgens (male sex hormones) as a byproduct.
Effects: In 46,XX individuals, the excess prenatal androgens can cause virilization of the external genitalia — ranging from mild clitoral enlargement to genitalia that appear typically male. Internal reproductive organs (uterus, ovaries, fallopian tubes) typically develop normally. Classic CAH can also cause life-threatening salt-wasting crises in newborns if not identified and treated quickly.
Management: Lifelong corticosteroid replacement therapy (typically hydrocortisone in children, prednisone or dexamethasone in adults) to replace cortisol and suppress excess androgen production. During illness or surgery, stress-dose steroids are essential to prevent adrenal crisis. A 2018 clinical practice guideline from the Endocrine Society provides detailed management recommendations.
Androgen Insensitivity Syndrome (AIS)
Prevalence: Complete AIS (CAIS) occurs in approximately 1 in 20,000 to 1 in 64,000 XY births. Partial AIS (PAIS) is less well-characterized but estimated at similar or slightly higher rates.
What it is: AIS is caused by mutations in the androgen receptor gene on the X chromosome. In complete AIS, the body's cells cannot respond to testosterone at all. In partial AIS, the response is reduced but not absent.
Effects: Individuals with CAIS have 46,XY chromosomes and internal testes (often undescended) but develop typically female external genitalia, a shorter vagina, and breast development at puberty due to aromatization of testosterone to estrogen. They do not have a uterus or ovaries, and they do not menstruate. Many individuals with CAIS are not diagnosed until puberty, when menstruation fails to begin, or during fertility evaluation. Individuals with PAIS may have ambiguous genitalia at birth.
Management: Historically, undescended testes were removed in infancy or childhood due to concerns about gonadal tumor risk. Current evidence and Endocrine Society guidelines suggest that the cancer risk in CAIS is lower than previously thought (approximately 2-3% lifetime risk), and gonadectomy can be deferred to allow natural pubertal development. If gonads are removed, lifelong hormone replacement therapy is necessary.
Klinefelter Syndrome (47,XXY)
Prevalence: Approximately 1 in 500 to 1 in 1,000 male births — one of the most common chromosomal variations in humans.
What it is: Individuals have an extra X chromosome (47,XXY instead of 46,XY). Most are identified as male at birth and raised as boys.
Effects: The extra X chromosome affects testicular function. After puberty, many individuals produce less testosterone than typical, leading to smaller testes, reduced muscle mass, gynecomastia (breast tissue development), sparse body hair, and often — though not always — infertility. Cognitive and behavioral effects can include language delays in childhood and increased risk of learning disabilities, though intelligence is typically in the normal range. Many people with Klinefelter syndrome are never diagnosed — a 2019 study in Human Reproduction Update estimated that only about 25% of cases are identified during the individual's lifetime.
Management: Testosterone replacement therapy beginning at puberty can support masculinization, bone density, muscle mass, energy levels, and mood. Fertility options including testicular sperm extraction (micro-TESE) and assisted reproduction have expanded in recent years. Monitoring for metabolic syndrome, osteoporosis, and cardiovascular risk is recommended, as these are elevated in Klinefelter syndrome.
Turner Syndrome (45,X)
Prevalence: Approximately 1 in 2,000 to 1 in 2,500 female births.
What it is: Individuals have a single X chromosome instead of the typical two (45,X), or have structural abnormalities in one X chromosome. Mosaic forms (some cells 45,X, others 46,XX) also occur.
Effects: Turner syndrome affects ovarian development — streak gonads replace functional ovaries in most cases, leading to absent puberty and infertility without intervention. Other features can include short stature, a webbed neck, cardiac defects (especially bicuspid aortic valve and coarctation of the aorta), kidney abnormalities, and autoimmune thyroid disease. Cognitive function is typically normal, though some individuals have difficulty with spatial reasoning and mathematics.
Management: Growth hormone therapy in childhood to address short stature. Estrogen replacement therapy beginning around age 11-12 to induce puberty and support bone health, followed by combined estrogen-progestogen therapy. Lifelong cardiac monitoring is critical — aortic dissection is a leading cause of premature death in Turner syndrome. A 2017 clinical practice guideline in European Journal of Endocrinology provides comprehensive management recommendations.
Other Important Variations
Beyond the four conditions above, the intersex spectrum includes many additional variations:
5-alpha reductase deficiency affects 46,XY individuals whose bodies cannot convert testosterone to dihydrotestosterone (DHT), the hormone responsible for virilization of external genitalia in utero. These individuals may be born with genitalia that appear female or ambiguous, but undergo significant virilization at puberty when testosterone levels surge. This condition has been extensively studied in certain populations in the Dominican Republic and Papua New Guinea.
Ovotesticular DSD (historically called "true hermaphroditism") is a rare condition in which both ovarian and testicular tissue are present — either in separate gonads or within a single gonad (ovotestis). External genitalia can range from typically female to typically male to ambiguous. Most documented cases have a 46,XX karyotype.
Swyer syndrome involves 46,XY individuals who have streak gonads instead of testes, typically due to mutations in or deletions of the SRY gene. External genitalia and internal structures (uterus, fallopian tubes) are typically female. Without functional gonads, puberty does not occur spontaneously and requires hormone therapy. Notably, individuals with Swyer syndrome who receive donor eggs can become pregnant and carry a pregnancy, since the uterus is present and functional.
Gonadal dysgenesis is a broader category that includes partial or complete failure of gonad development, which can occur in individuals with various karyotypes. Mixed gonadal dysgenesis (often associated with 45,X/46,XY mosaicism) involves a testis on one side and a streak gonad on the other.
Each of these conditions has its own medical considerations, monitoring needs, and treatment options. What they share is that they challenge the assumption that sex is a simple binary determined by a single factor.
The Surgery Debate: Consent, Timing, and Human Rights
Perhaps no aspect of intersex healthcare generates more controversy than the practice of performing "normalizing" genital surgery on intersex infants and children — procedures intended to make ambiguous genitalia conform more closely to typical male or female appearance.
These surgeries became standard practice in the mid-20th century, largely influenced by the work of psychologist John Money at Johns Hopkins University, who theorized that gender identity was entirely socially constructed and that any child could be successfully raised as either sex if the assignment was made early and reinforced consistently. This theory was later discredited — most notoriously through the case of David Reimer, a non-intersex boy who was raised as female after a circumcision accident and ultimately rejected the female assignment, suffering severe psychological harm before dying by suicide in 2004.
Despite the discrediting of Money's theory, early genital surgery on intersex infants continued as standard practice for decades. The rationale shifted to claims about psychosocial wellbeing — the idea that children with atypical genitalia would suffer social stigma, parental rejection, or identity confusion.
What the evidence says
Multiple studies and systematic reviews have challenged these claims. A Global DSD Update Consortium report, signed by specialists from 50 countries, acknowledged that evidence supporting early surgery for cosmetic reasons is weak and that outcomes data are poor. A 2019 review in the Journal of Pediatric Urology found that outcomes of feminizing genitoplasty (clitoral reduction, vaginoplasty) in childhood were associated with high rates of reoperation, reduced genital sensitivity, and patient dissatisfaction in adulthood.
Adult intersex individuals have increasingly spoken out about the lasting harm of surgeries performed without their consent. In a landmark 2017 survey by interACT (Advocates for Intersex Youth) and Lambda Legal, a majority of intersex respondents reported negative outcomes from childhood genital surgeries, including chronic pain, loss of sexual sensation, emotional distress, and the feeling that a fundamental decision about their body was made for them before they could participate.
The shift toward informed consent
Major medical and human rights organizations have increasingly moved toward recommending that medically unnecessary surgeries on intersex children be deferred until the individual is old enough to participate in the decision.
- In 2013, the United Nations Special Rapporteur on Torture called non-consensual intersex surgeries a form of inhuman treatment.
- In 2017, a coalition of former US Surgeons General called for an end to medically unnecessary surgeries on intersex children.
- The Endocrine Society 2018 guidelines recommend multidisciplinary care teams and emphasize shared decision-making with families, while acknowledging the trend toward deferral of elective surgery.
- In 2020, Lurie Children's Hospital in Chicago became the first US hospital to publicly apologize for performing non-consensual intersex surgeries and to adopt a policy of deferral.
- Several countries, including Germany (2021) and Greece (2022), have enacted legislation restricting non-emergency intersex surgeries on minors.
The key distinction is between medically necessary interventions (such as addressing urinary obstruction, or life-threatening salt-wasting in CAH) and cosmetic or normalizing procedures (such as clitoral reduction or gonadectomy performed solely to make the body conform to binary expectations). The former remain uncontroversial; the latter are increasingly recognized as procedures that should await the individual's informed consent.
Healthcare Needs Throughout Life
Intersex variations are not conditions to be "fixed" and forgotten. Many require ongoing medical monitoring, hormone management, and preventive care across the lifespan. Yet healthcare systems often fail intersex individuals — either through ignorance of their specific needs or through a clinical culture that treats intersex bodies as problems to be corrected rather than variations to be supported.
Hormone therapy and monitoring
Many intersex individuals require some form of hormone therapy — either because their bodies do not produce adequate hormones (as in Turner syndrome after gonadectomy, or Swyer syndrome) or because they need hormone supplementation to support bone density, cardiovascular health, and metabolic function (as in Klinefelter syndrome).
Hormone management for intersex individuals shares much with transgender hormone therapy but involves distinct considerations. Dosing, timing of initiation, and monitoring protocols depend on the specific variation, the presence or absence of gonads, and the individual's goals. The Endocrine Society's 2018 clinical practice guideline on DSD management provides evidence-based recommendations, but many endocrinologists outside of specialized centers have limited experience with these protocols.
For individuals on hormone replacement, consistent tracking of how you feel — energy levels, mood, sleep quality, any side effects — provides valuable data for appointments with your endocrinologist. Apps like WatchMyHealth that allow you to log medications and track symptoms over time can help you and your doctor spot trends and adjust dosing more precisely than relying on memory alone.
Bone density
Osteoporosis risk is elevated in several intersex conditions, particularly Turner syndrome, Klinefelter syndrome, and any condition involving gonadectomy without adequate hormone replacement. The Endocrine Society recommends regular bone density screening (DEXA scans) and attention to calcium, vitamin D, and weight-bearing exercise.
Cardiovascular health
Turner syndrome carries significantly elevated cardiovascular risk, including aortic dilation and dissection. Regular cardiac imaging is essential. Klinefelter syndrome is associated with increased rates of metabolic syndrome, type 2 diabetes, and venous thromboembolism. Proactive cardiovascular screening and metabolic monitoring are recommended for both conditions.
Fertility
Fertility considerations vary widely across intersex conditions. Some individuals are fertile without intervention. Others may benefit from assisted reproductive technologies. Still others will not be able to have genetically related children. What matters is that fertility counseling be offered early enough — ideally before any irreversible interventions — and that individuals have access to honest, compassionate information about their options.
A 2020 review in Fertility and Sterility by Finlayson and colleagues found that fertility preservation options for intersex individuals have expanded significantly but remain inconsistently offered. Many individuals reported learning about their condition's fertility implications only in adulthood, sometimes after gonadectomy had already eliminated options that might have been preserved.
Mental Health and Psychosocial Support
The psychological impact of intersex variations is shaped not primarily by the biology itself but by how that biology is treated by families, healthcare systems, and society.
A 2018 study in the European Journal of Endocrinology found that adults with DSD/intersex conditions reported higher rates of psychological distress than the general population — but that the strongest predictors of distress were not the medical condition itself. Instead, they were factors like secrecy (being told not to discuss one's condition), shame (internalizing the idea that one's body is defective), non-consensual medical procedures in childhood, and lack of peer support.
Conversely, intersex individuals who had access to peer communities, who received honest and age-appropriate information about their bodies, and who participated in decisions about their own care reported significantly better psychological outcomes.
These findings have driven a shift in clinical recommendations. The 2018 Endocrine Society guidelines explicitly recommend psychological support as a core component of DSD management — not as an afterthought but as a parallel track alongside any medical intervention. Peer support organizations, including interACT, the AIS-DSD Support Group, and CARES Foundation (for CAH), provide community connections that clinical care alone cannot replicate.
For anyone navigating questions about their body, their diagnosis, or their identity, regular self-reflection can be a helpful tool. Journaling about how you feel physically and emotionally — and tracking those patterns over time — creates a record that can be valuable both for your own self-understanding and for conversations with therapists or counselors. WatchMyHealth's wellbeing and journal features are designed for exactly this kind of longitudinal self-tracking.
What Intersex Is Not
Misunderstandings about intersex are widespread, and they contribute to stigma, inappropriate medical treatment, and social marginalization. A few clarifications are worth stating explicitly.
Intersex is not the same as transgender. Intersex refers to biological variations in sex characteristics. Transgender refers to a gender identity that differs from the sex assigned at birth. Some intersex people are also transgender; most are not. The two categories describe different phenomena and should not be conflated.
Intersex is not a disorder. While the clinical term "disorders of sex development" (DSD) is still used in medical literature, many intersex individuals and advocacy organizations object to the word "disorder," preferring "differences" or "variations" of sex development. The concern is that pathologizing language frames natural biological diversity as inherently broken, reinforcing the idea that intersex bodies need to be "corrected." The shift in language reflects a broader move in medicine toward depathologizing human variation — similar to the evolution in how autism and homosexuality are discussed.
Intersex is not extremely rare. As discussed above, even conservative estimates place intersex prevalence at roughly 1 in 5,500 births — comparable to cystic fibrosis. Broader definitions yield estimates of 1 in 60 to 1 in 200. The perception of extreme rarity is partly an artifact of secrecy: for decades, intersex individuals and their families were counseled to keep the condition hidden, creating the illusion that it was far less common than it actually is.
Intersex does not determine gender identity. Research consistently shows that intersex individuals identify across the gender spectrum — most identify with the gender they were assigned at birth, some do not. A 2016 study in Journal of the Endocrine Society found that approximately 85-90% of individuals with DSD were satisfied with their assigned gender, though satisfaction rates varied significantly across different conditions and depended heavily on whether the individual felt their assignment was made with their wellbeing — rather than anatomical appearance — as the priority.
For Healthcare Providers: Doing Better
Many intersex individuals report negative healthcare experiences — not from malice but from provider ignorance. A 2015 survey by the Endocrine Society found that the majority of general practitioners and even many endocrinologists had received no formal training on intersex/DSD conditions during medical school or residency.
Clinicians can improve care by taking several evidence-based steps:
Use respectful, patient-centered language. Ask patients what terms they prefer for their condition and their body. Avoid language that implies defectiveness. The shift from "disorder" to "difference" of sex development reflects this principle.
Involve patients in decision-making. The era of paternalistic, doctor-knows-best management of intersex conditions is ending. Shared decision-making — where the clinician provides information and recommendations, and the patient (or, for children, the patient and family) actively participates in the choice — is now the standard of care recommended by the Endocrine Society, the American Academy of Pediatrics, and multiple European guidelines.
Provide access to peer support. Clinical care cannot replace the value of connecting with others who share your experience. Referring patients and families to organizations like interACT, the AIS-DSD Support Group, the CARES Foundation, and the Turner Syndrome Society can significantly improve psychosocial outcomes.
Ensure continuity across the lifespan. Many intersex individuals experience a gap in care during the transition from pediatric to adult healthcare. Structured transition planning — ideally beginning in early adolescence — reduces the risk of patients falling through the cracks at a critical developmental stage.
Offer comprehensive screening. Depending on the specific variation, individuals may need monitoring for cardiovascular health, bone density, metabolic function, gonadal tumor risk, and fertility. These screening protocols are well-documented in Endocrine Society and European guidelines but require clinicians to know they exist.
Living With an Intersex Variation: Practical Steps
Whether you have recently learned about an intersex variation — in yourself or in your child — or have been managing one for years, several practical steps can support your health and wellbeing.
Learn about your specific variation. Not all intersex conditions are alike. Understanding the biology, health implications, and monitoring needs of your particular variation empowers you to advocate for yourself in clinical settings. Peer support organizations often provide condition-specific educational resources that are more accessible than medical journals.
Build a multidisciplinary care team. Ideal care involves endocrinology, urology or gynecology, genetics, psychology, and — depending on the condition — cardiology, fertility specialists, and other disciplines. If you are not near a specialized center, telemedicine has expanded access to expert consultation.
Keep detailed health records. Intersex variations often involve multiple specialists, long-term hormone monitoring, and periodic screening tests. Maintaining your own records — including medication doses, lab results, symptoms, and how you feel day to day — ensures continuity even when you switch providers. WatchMyHealth's medication tracking and symptom logging features can serve as a personal health diary that complements your medical chart.
Prioritize mental health. The psychological impact of living with a stigmatized condition should not be underestimated. Therapy — particularly with a provider who has experience with DSD/intersex issues — can be valuable. Regular mood and wellbeing tracking helps you notice patterns and address dips before they become crises.
Connect with community. Isolation is one of the most consistently reported challenges among intersex individuals. Whether through online communities, local support groups, or advocacy organizations, connecting with others who share your experience can be profoundly validating.
Know your rights. Depending on your jurisdiction, legal protections for intersex individuals may include anti-discrimination laws, restrictions on non-consensual surgery, and the ability to designate a non-binary gender marker on identity documents. Advocacy organizations can provide jurisdiction-specific legal information.
The Bigger Picture: Why This Matters for Everyone
You do not need to be intersex for this topic to matter to you. Understanding intersex variations has implications that extend well beyond the directly affected population.
For science literacy: The binary model of sex — while useful as a first approximation — is an oversimplification of how sex development actually works at the genetic, hormonal, and anatomical levels. Understanding intersex biology makes you a better-informed reader of health news, genetics research, and public health policy.
For parenting: If you become a parent, there is a reasonable chance your child will be born with some variation in sex development. Knowing that these variations exist, that they are not emergencies (with specific medical exceptions like salt-wasting CAH), and that cosmetic surgery can wait for the child's own input can prevent decisions made in panic from causing lasting harm.
For healthcare advocacy: Whether you are navigating your own healthcare or supporting a family member, understanding the principles of informed consent, shared decision-making, and patient-centered care makes you a more effective advocate. These principles apply far beyond intersex healthcare.
For basic human decency: Intersex individuals have historically been subjected to medical procedures without their consent, pressured into secrecy about their bodies, and excluded from public conversations about sex and gender. Greater public understanding is a prerequisite for the cultural change that allows intersex people to live without shame, access appropriate healthcare, and participate fully in society.
The science is clear: human sex development is not a binary toggle. It is a complex biological process with many possible outcomes, most of which are compatible with healthy, fulfilling lives — provided that healthcare systems, families, and communities respond with knowledge rather than fear, and with respect rather than a compulsion to "fix" what is simply different.
